NEW YORK (PRWEB)
April 11, 2020

On April 9th, 2020 the New York Supreme Court, Appellate Division, First Department, affirmed the trial court’s decision in Nemeth v. Brenntag North America, et al., Case No. 9765, New York County Index No. 190138/14, denying the defendant’s post-trial motions.

The plaintiffs, Florence and Frank Nemeth of Lake Ronkonkoma, New York, sued several manufacturers and distributors of asbestos-containing products, including a distributor of talcum powder named Whittaker Clark & Daniels, Inc. (“WCD”), after Florence was diagnosed with mesothelioma following years of using talcum powder in a product called Desert Flower, the talc for which WCD had sourced from asbestos-containing mines.

Florence succumbed to the disease before trial, and was survived by her husband Frank and their two children and four grandchildren.

The plaintiffs won a jury verdict against WCD, and WCD appealed, arguing (among other things) that the Nemeths couldn’t prove that WCD’s asbestos-containing talcum powder caused Florence’s mesothelioma.

A panel for the First Department rejected WCD’s arguments, holding that “the trial record contains sufficient evidence, consistent with the Court of Appeals’ reasoning in Parker v. Mobil Oil Corp. (7 NY3d 434 [2006]), to support the jury’s verdict and conclusion that Nemeth was exposed to a sufficient quantity of asbestos to cause the disease.”

Indeed, Plaintiffs’ geologist and testing expert testified for the jury that a typical use of a cosmetic talc product would have released approximately 2.7 million individual asbestos fibers. This meant that over Florence’s years of use, she was exposed to billions or trillions of asbestos fibers in her home’s bathroom.

In reaching its decision, the appellate court clarified that a 2017 First Department decision, Matter of N.Y.C. Asbestos Litigation (Juni) (148 AD3d 233 [1st Dept 2017]) did not upend decades of New York law and practice regarding proof of causation in asbestos cases.

Finally, the appellate court recalculated a damages setoff, and accordingly increased the amount of plaintiffs’ net verdict from $2,933,750 to $3,300,000.

“It is gratifying, after such a lengthy trial and appellate process to see the Appellate Court render such a well-reasoned and supported decision on behalf of our deserving client”, said Robert Komitor, a partner at Levy Konigsberg. “Today’s decision is important not just for vindicating the rights of a loyal talcum powder product user who was exposed to asbestos in a product that contained no warning, but for consumers everywhere hoping to get a full and fair opportunity to prove their case in court,” said Renner Walker, a Levy Konigsberg attorney who litigated the appeal.

About Levy Konigsberg LLP

Levy Konigsberg LLP (LK) (https://www.levylaw.com) has established itself as one of the nation’s premier law firms featuring highly acclaimed trial lawyers who have won some of the nation’s largest jury verdicts. With over 30 years of experience, the firm prides itself on the accomplishments attained by its lawyers in high-stakes cases involving mesothelioma, lead poisoning, sex abuse, defective products, whistleblower law, and medical malpractice. LK has litigated and won precedent-setting cases and obtained highly-publicized rulings and judgments, including some of the highest awards for our clients in numerous areas of litigation.

Share article on social media or email:

AUSTIN, Texas (PRWEB)
April 11, 2020

CureCompanion and AAPI (American Association of Physicians of Indian Origin) are pleased to announce that they have entered into a strategic partnership to offer CureCompanion’s telemedicine platform to members of AAPI.

CureCompanion is a comprehensive telemedicine software platform that facilitates telemedicine visits between healthcare providers and patients. As part of this partnership, AAPI’s members will be able to use CureCompanion to conduct video visits with their patients using their own mobile phones, tablets, and computers. “Our solution will provide AAPI members a simple and effective tool to manage their patients’ care virtually during the current coronavirus pandemic and beyond,” said Mukul Majmudar, CEO of CureCompanion.

AAPI is promoting CureCompanion as the exclusive telemedicine platform partner to its physician members. Dr. Suresh Reddy, president of AAPI, said, “This partnership will allow our members to continue offering their patients a high standard of care through virtual visits. Thanks to CureCompanion, patients don’t need to come into their doctor’s office to receive the essential care they need, which is critical during this COVID-19 crisis.”

For more information and to sign up for CureCompanion’s AAPI member plan, members can contact AAPI at info@aapiusa.org.

About CureCompanion

CureCompanion is a robust telemedicine platform with easy-to-use mobile and web apps for healthcare providers, professionals, and patients. It provides a full suite of features including HD video calls, appointments, patient records and SOAP notes. CureCompanion also offers integrated hardware solutions such as its enterprise telemedicine cart and portable telemedicine kit for clinical settings.

About AAPI

Founded in 1982, the American Association of Physicians of Indian Origin (AAPI) represents a conglomeration of more than 80,000 practicing physicians in the United States. AAPI is a forum to facilitate and enable Indian American Physicians to excel in patient care, teaching and research and to pursue their aspirations in professional and community affairs.

Share article on social media or email:

IRVINE, Calif. (PRWEB)
April 11, 2020

Onsite Dental and Virtual Dental Care are pleased to announce Onsite Dental’s implementation of Virtual Dental Care’s Teledentix platform.

“Teledentistry visits using Teledentix are an additional option for patients to seek advice from our affiliated board-certified dentists in real-time, from the safety of their own home during these difficult times,” said Ern Blackwelder, Onsite Dental’s CEO. “Our goal is to give patients a high quality, virtual, face-to-face dental consultation that addresses their concerns and gives them an evaluation of their need for an emergency office visit, while reducing the risk of COVID-19 exposure for everyone involved.”

Conducted using secure HIPAA compliant video conferencing from Virtual Dental Care, Inc., Onsite Dental’s affiliated dentists can assess the symptoms that a patient is experiencing and, using the camera, get a visual sense of swelling, infection, and staining as well as walk the patient through procedures they can do at home. This information is important in determining the best next steps for the patient. If an office visit is determined to be necessary, patients are screened in advance for COVID-19 symptoms and risk factors, including fever.

“We launched our teledentistry program as a response to meet the demand for emergency care that continues to grow as the COVID-19 pandemic is prolonged and in our attempt to keep dental emergencies away from the valuable resources of the emergency room,” added Mr. Blackwelder. “But, since we pride ourselves in offering the latest technological advancements in the field, we intend to work with Virtual Dental Care going forward as an additional means of enhancing our ability to communicate in different ways with our patients.”

ABOUT ONSITE DENTAL

Founded in 1997, Onsite Dental pioneered the concept of bringing high-quality comprehensive dental care directly to the workplace to help employees improve their oral health. The company serves leading corporations, universities and unions in 12 states. Due to the COVID – 19 pandemic, Onsite Dental has suspended all elective or non-emergency dental procedures, but it has remained open for patients with dental emergencies.

ABOUT VIRTUAL DENTAL CARE, INC.

Virtual Dental Care, Inc. is the industry’s leading provider of a robust proprietary Software-as-a-Service platform that supports all aspects of teledentistry delivery. The platform is called Teledentix. The Company’s vision is that teledentistry will become a widely used industry norm, expanding dentistry and a dentist’s role beyond the walls of a dental office – even into the broader healthcare system. Virtual Dental Care will supply the necessary software solutions to facilitate the rapid adoption of teledentistry.

Share article on social media or email:

STONY BROOK, N.Y. (PRWEB)
April 11, 2020

CytoGenX recognizes the need for rapid diagnostic testing for the at-risk pregnant population. CytoGenX understands the enormous stress that the COVID-19 outbreak places on families that are currently pregnant. CytoGenX continues to provide the fastest confirmation available of abnormal prenatal screening results from NITP, maternal serum screening and ultrasounds. Pregnant women normally have weekly prenatal visits with their healthcare providers. However, in light of the COVID-19 outbreak, prenatal visits are being limited to lower the risk of COVID-19 exposure. This leads to screening tests also being delayed and offered only during the anatomy scan at 20 weeks gestation. Results of these tests can take up to 2 weeks to report placing enormous and often unnecessary stress on an expectant mother. If a genetic abnormality is suspected at 22 weeks gestation confirmatory diagnostic testing needs to be performed in a center that can issue those results as quickly as possible. CytoGenX can issue confirmatory results in as little as 24 hours.

The American College of Obstetricians and Gynecologists (ACOG) issued a statement that “pregnant women may be at higher risk of severe illness, morbidity, or mortality compared with the general population,” likely due to physiologic changes that happen during pregnancy, and because pregnancy constitutes “a state of relative immunosuppression as compared to non-pregnancy.” Additionally, pregnant women normally experience and increased heart rate, diminished lung capacity and are at risk for gestational diabetes all of which can lead to increased vulnerability of severe respiratory problems if infected with COVID-19. To date there is no evidence of vertical transmission (mother to fetus) of COVID-19. However, UC Berkeley researchers have shown that high fever during the first three to eight weeks of pregnancy may lead to abnormal development in the fetus specifically the heart and jaw.

Additionally, the Slone Epidemiology Center at Boston University and the CDC have reported a link to fever and neural tube defects. They report that the consumption of 400 micrograms of folic acid every day may reduce the risk of fever induced neural tube defects. The SMFM has recently released guidance regarding COVID-19 and antenatal surveillance: “Very little is known about the natural history of pregnancy after a patient recovers from COVID-19. Given how little is known about this infection, a detailed mid-trimester anatomy ultrasound examination may be considered following first-trimester maternal infection. For those experiencing illness later in pregnancy, it is reasonable to consider sonographic assessment of fetal growth in the third trimester” As these same abnormal ultrasound findings may have a genetic basis rather than a consequence of maternal hyperthermia. It is important to quickly determine if abnormal fetal anatomy has a genetic basis. A positive genetic test would allow for more accurate phenotype prediction.

It is extremely important that pregnant women have access to necessary prenatal care. The COVID-19 outbreak should not compromise the monitoring of ongoing pregnancies by the prenatal healthcare professionals. By partnering with OB/GYN and MFM practices CytoGenX strives to help maintain direct access of diagnostic genetic testing for all pregnant women. CytoGenX offers 24 hour confirmatory testing coupled with immediate access to comprehensive diagnostic testing. For more information about CytoGenX, visit them online https://cytogenx.com.

Share article on social media or email:

BALTIMORE (PRWEB)
April 11, 2020

RMS Omega Technologies announced today the release of a rapidly deployable mobile solution developed for patient registration, positive identification and geographical tracking of virus spread. The solution is easy to implement at mobile, drive-through, and exterior medical testing locations as well as future vaccination sites. The mobile system was developed from collaborative efforts among the company’s hardware and software vendors to further support healthcare organizations in virus testing and tracking efforts amid the COVID-19 pandemic.

The mobile system allows healthcare workers on the front lines to safely register and identify patients using their driver’s license or government-issued ID. Within four seconds, identification is scanned from the patient’s hand, at a safe distance, using a rugged and cleanable mobile device. The software even collects the face image from an ID for visible account verification. An account or patient record is instantly created before specimen collection. Healthcare technicians can record symptoms, print specimen labels using a mobile label printer, and update testing results as they are received.

Once patient data is sent to the hospital system and an account is created, all personal information is cleared from the mobile device for patient safety and security in compliance with HIPAA regulations. When data is entered into the hospital system, patient history and existing records can be reconciled. If necessary, the application can connect with all major hospital and EMR systems including EPIC, Cerner, and more.

The mobile application, CaptureMax Healthcare, also provides essential analytical data using heat maps to track testing results and virus spread using the patient’s permanent address on their government-issued ID. Location access can include personalized views including local, state, or country levels to track and monitor virus spread or vaccination percentages in certain geographic locations. Only certain access levels can reach the database with secure login tiers.

“Over the past 21 years, RMS Omega continues to answer the call of healthcare organizations across the United States and Canada,” says Peter Vatenos, VP of Marketing & Product Development at RMS Omega. “We are always searching for a better way to serve our healthcare partners and assist in the improvement of specimen collection and processing procedures, tracking, and data analytics for increased safety and accuracy.”

RMS Omega’s mobile patient identification system is available now and can be deployed immediately. For more information, please visit https://rmsomega.com/healthcare/mobile-patient-id-tracking-solution/.

About RMS Omega Technologies:

RMS Omega is a strategic technology provider for RFID, barcode, advanced data collection and location technology, wireless and mobility solutions. We partner with healthcare organizations throughout the United States and Canada to increase patient safety through vital point of care technology systems.

As a result of the COVID-19 pandemic, RMS Omega is currently supplying labels for COVID-19 test kits, patient wristbands, and essential point of care technology to our healthcare workers on the front lines. We are supporting numerous supply chains with shipping labels, printing supplies, advanced data collection and tracking technologies to help keep the flow of goods to those who need them. We are continuing to provide repair and support services to make sure the organizations we serve are functioning to the best of their ability. As a company, we vow to do anything we can to support our customers in a time of need. We encourage you to please reach out to our team if you require support, inventory or guidance. We are here to help.

Share article on social media or email: